期刊文献+

糖尿病肾病患者尿基质金属蛋白酶组织抑制剂水平的变化及其意义 被引量:4

原文传递
导出
摘要 目的 探讨 2型糖尿病患者尿中基质金属蛋白酶组织抑制剂水平的变化及其与糖尿病肾损害的关系。方法 采用酶联免疫吸附法对 78例 2型糖尿病患者及 30例正常人尿中基质金属蛋白酶组织抑制剂水平进行检测。结果 糖尿病各组患者尿中基质金属蛋白酶组织抑制剂水平均明显高于对照组 (P <0 .0 1) ;糖尿病患者各组间尿基质金属蛋白酶组织抑制剂水平差异显著 ,随 2 4h尿白蛋白排泄量的增加而递增 ,尿中基质金属蛋白酶组织抑制剂水平与 2 4h尿白蛋白排泄量、尿N 乙酰 β 氨基葡萄糖苷酶 (NAG)含量呈显著正相关。结论 糖尿病患者尿中基层蛋白酶组织抑制剂水平随糖尿病肾病的严重程度而明显增高 ,可作为糖尿病肾病早期诊断的敏感指标。
出处 《中国综合临床》 北大核心 2004年第11期1008-1009,共2页 Clinical Medicine of China
  • 相关文献

参考文献9

  • 1Collen A, Hanemaaijer R, Lupu F, et al. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix [J]. Blood,2003,101 ( 5 ): 1810-1817.
  • 2Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: a novel therapeutic target [ J ]. J Clin Pharmacol,1997,37 ( 11 ) :991-1000.
  • 3Gomez DE, Alonso DF, Yoshiji H,et al. Tissue inhibitors of metalloproteinases: Structure regulation and biological functions[J]. Eur J Cell Biol, 1997,74 (2): 111-122.
  • 4Wu K,Setty S. Altered kidney matrix gene expression in early stages of experimental diabetes [J]. Acta Anat ( Basel ), 1997,158(3):155-165.
  • 5Suzuki D,Miyazaki M,Jinde K,et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen In diabetic nephropathy[ J]. Kidney Int, 1997,52(1) :111-119.
  • 6Mlennan SV, Martell SY, Yue DK. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation[J]. Diabetologia,2000,43 (5) :642-648.
  • 7Horstrup JH, Gehrmann M, Schneider B, et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease [J]. Nephrol Dial Transplant, 2002,17(6): 1005 -1013.
  • 8Chromek M, Tullus K, Hertting O, et al Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Acute Pyelonephritis and Renal Scarring[J]. Pediatr Res,2003,53(4) :698-705.
  • 9汤珣.慢性肾炎患者血清TIMP-1浓度的变化及氯沙坦治疗对TIMP-1浓度的影响[J].第一军医大学学报,2003,23(9):966-969. 被引量:4

二级参考文献18

  • 1李琦,李湘平,梁勇,刘雄.下咽癌中基质金属蛋白酶-2的表达及其临床意义[J].第一军医大学学报,2003,23(5):495-497. 被引量:2
  • 2Border WA, Noble NA. Interaction of transforming growth factorbeta and angiotensin Ⅱ in renal fibrosis[J]. Hypertansion, 1998, 31(1tp2): 181-8.
  • 3Mtojima M, Kakuchi J, Yoshioka T. Association of TGF-β signaling in angiotensin Ⅱ -induced PAI-Ⅰ mRNA upregulation in mesangial cells: role for PKC[ J ]. Biochim Biophys Acta, 1999, 1449(3): 216-7.
  • 4Chung KY, Agarwal A, Uitto A, et d. An AP-1 binding sequence is essential for regulation of the human alpha 2 ( Ⅰ ) collagen (COLIA2) promoter activity by transforming growth favor-beta[J]. J Biol Chem, 1996, 271(54): 3272-8.
  • 5Khasigov PZ, Ktzoeva SA, Cratagonova TM. Role ofmalrix metalloproteinase in development of diabetic nephropathy[ J ]. Biochemistry(Mosc), 2000, 65(5): 519-24.
  • 6Akiyama K, Shikata K, Sugimoto H, et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitor of metalloproteinases and type Ⅳ collagen in patients with various types of glomerulonephritis[J]. Res Commun Mol Pathol Pharmacol, 1997,95(2): 115-28.
  • 7Maxwell Pit, Timms PM, Chaadran S. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes[J]. Diabet Med, 2001, 18(10): 777-80.
  • 8Nakamura T. Elevation of serum levels of metalloproteinase- 1, tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease[J].Am J Nephrol, 2000, 20(1): 32-6.
  • 9Gomez DE, Alonso DF, Yoshiji H,et al. Tissue inhibitors of metalloproteinases: Structure regulation and biological functions[J]. Eur J Cell Biol, 1997, 74(2): 111-22.
  • 10Li J, Rosman AS, Leo MA, et al. Tissue inhibitor of metalloproteinase is inereased in the serum of precirrhotie and cirrhotic alcoholic patient and can serve as a marker of fibrosis[J]. Hepatology,1994, 19(6): 1418-23.

共引文献4

同被引文献39

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部